Hence, IBD characterized by self-directed inflammation, where the activation of innate immune cells plays a critical role in pathogenesis, appears to be a particularly promising target for the implementation of HO-1 inducers as immunomodulators. Here, HMOX1 is linked to inflammatory bowel disease.